安罗替尼治疗表皮生长因子受体野生型老年晚期非小细胞肺癌病人的临床疗效

doi:10.3969/j.issn.1003-9198.2021.01.017

摘要/Abstract

摘要： 目的观察盐酸安罗替尼治疗表皮生长因子受体(EGFR)野生型老年晚期非小细胞肺癌(NSCLC)病人的疗效和安全性。方法选择2018年6月至2019年3月我院肿瘤科就诊的EGFR野生型老年晚期NSCLC病人,常规给予安罗替尼12 mg/次,1次/d,连续服药2周,停药1周,即3周为1个疗程。记录病人无进展生存期(PFS)、客观缓解率(ORR)、疾病控制率(DCR)及不良反应发生情况。结果共纳入26例病人,年龄66~85岁,中位年龄74.5岁;一线治疗21例,二线治疗3例,三线治疗2例。截至2019年10月10日,26例病人ORR为11.54%、DCR为76.92%、PFS为5.1个月。常见的不良反应为高血压、手足综合征、疲劳乏力、咯血、甲状腺功能异常等,不良反应经对症处理及安罗替尼暂停、减量后均可控制,未出现药物相关的死亡。结论安罗替尼在EGFR野生型晚期老年NSCLC病人的治疗中,病人的PFS有延长趋势,ORR及DCR较高,不良反应可控。

关键词: 安罗替尼, 非小细胞肺癌, 老年人

Abstract: Objective To evaluate the efficacy and safety of anlotinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC) with wild-type epidermal growth factor receptor (EGFR). Methods From June 2018 to March 2019, elderly patients with advanced NSCLC with wild-type EGFR were selected as the subjects. They underwent 2 weeks of treatment with anlotinib (12 mg/d) and 1 week of withdrawal, and 3 weeks was a course of treatment. The patients' objective response rate (ORR), disease control rate (DRR), progression free survival (PFS) and adverse reaction were recorded. Results A total of 26 patients aged 66-85 years, with a median age of 74. 5 years, were enrolled in this study. Among them, 21 cases were treated with first-line, 3 cases were treated with second-line and 2 cases were treated with third-line treatment. As of October 10, 2019, the patients' ORR was 11. 54% (3/26), DRR was 76. 92% (20/26), and the median PFS was 5. 1 months. The common adverse events were hypertension, hand-foot syndrome, fatigue, hemoptysis, thyroid dysfunction. No drug-related mortality occurred. Conclusions In the treatment of elderly patients with advanced NSCLC with wild-type EGFR, anlotinib could prolong the patients' PFS, improve ORR and DCR, and the adverse reactions are controllable.

Key words: anlotinib, non-small cell lung cancer, aged

中图分类号:

R 734.2

谢强, 朱金秀, 臧焕平, 林恒. 安罗替尼治疗表皮生长因子受体野生型老年晚期非小细胞肺癌病人的临床疗效[J]. 实用老年医学, 2021, 35(1): 65-68.

XIE Qiang, ZHU Jin-xiu, ZANG Huan-ping, LIN Heng. Efficacy of anlotinib in the treament of elderly patients with advanced non-small cell lung cancer with wild-type epidermal growth factor receptor[J]. Practical Geriatrics, 2021, 35(1): 65-68.

参考文献

[1] MIUER K D, GODING S A, ORTIZE A P, et al. Cancer statics for Hispanics/lations, 2018[J]. Cancer J Clin, 2018. DOI: 10.3322/caac.21494.
[2] LANG K, MARCINIAK M D, FARIES D, et al. Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small-cell lung cancer in the United States[J]. Lung Cancer, 2009, 63(2):264-270.
[3] JACOB S, HOVEY E, WENG N G, et al. Estimation of an optimal chemotherapy utilisation rate for lung cancer: an evidence-based benchmark for cancer care[J]. Lung Cancer, 2010, 69(3):307-314.
[4] DAVIDOFF A J, TANG M, SEAL B, et al. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer[J]. J Clin Oncol, 2010, 28(13):2191-2197.
[5] HAN B, LI K, WANG Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 Phase3 randomized clinical trial[J]. JAMA Oncol, 2018, 4(11):1569-1575.
[6] SI X, ZHANG L, WANG H, et al. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase Ⅲ trial of anlotinib in patients with advanced non-small cell lung cancer[J]. Lung Cancer, 2018, 122:32-37.
[7] SUN W, WANG Z, CHEN R, et al. Influences of anlotinib on cytochrome P450 enzymes in rats using a cocktail method[J]. Biomed Res Int, 2017. DOI: 10.1155/2017/3619723.
[8] KAMBA T, MCDONALD D M. Mechanisms of adverse effects of anti-VEGF therapy for cancer [J]. Br J Cancer, 2007, 96(12):1788-1795.
[9] RECK M, BARLESI F, CRINÒ L, et al. Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel ofexperts[J]. Ann Oncol, 2012, 23(5):1111-1120.
[10] SUN Y, NIU W, DU F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors[J]. J Hematol Oncol, 2016, 9(1):105.

[1]	丛晓飞, 李铭麟, 石春来. 老年口腔衰弱与多重用药的关系及干预策略[J]. 实用老年医学, 2024, 38(9): 872-875.
[2]	李毛毛, 张飞, 沈鑫, 李洁华. 老年人口腔衰弱与跌倒关系的研究进展[J]. 实用老年医学, 2024, 38(9): 876-879.
[3]	张飞, 李毛毛, 李铭麟, 王佳贺. 老年人口腔衰弱与抑郁症的相关性研究进展[J]. 实用老年医学, 2024, 38(9): 884-888.
[4]	李江, 邱雁, 王婷, 王丹, 虞一帆, 濮玲丽, 卜玲. 老年肺腺癌病人术前全身免疫炎症指数/血清白蛋白与临床病理特征的相关性研究[J]. 实用老年医学, 2024, 38(9): 893-896.
[5]	戴静, 崔焱. 糖化血红蛋白变异性与老年2型糖尿病病人认知功能障碍的相关性分析[J]. 实用老年医学, 2024, 38(9): 931-935.
[6]	张星星, 张海洋, 何小菁, 鲁翔. 不同肥胖指标与老年人糖尿病患病风险的调查研究[J]. 实用老年医学, 2024, 38(9): 940-943.
[7]	倪红艳, 陈云, 张其兵, 马一鸣, 解成兰. 电针对老年病人下肢骨科手术围术期认知功能及炎症因子的影响[J]. 实用老年医学, 2024, 38(9): 944-947.
[8]	李晓敏, 李晓林, 栗杰, 吴蕾, 郝冉冉. 老年病人经肛双气囊小肠镜进镜效率及其影响因素研究[J]. 实用老年医学, 2024, 38(9): 958-961.
[9]	蔡荟萃, 陈燕, 王燕, 叶劲军, 朱钰颖. 多形式健康教育模式联合简易呼吸功能锻炼对老年肺癌放疗病人癌因性疲乏及遵医行为的影响[J]. 实用老年医学, 2024, 38(9): 968-972.
[10]	李湘, 栗萱, 田应选. 肺衰老与慢性呼吸系统疾病研究现状及进展[J]. 实用老年医学, 2024, 38(8): 761-765.
[11]	王小娇, 王宁, 崔宏, 叶童, 王晓明. 运动康复对老年轻中度慢性心力衰竭病人的疗效评价[J]. 实用老年医学, 2024, 38(8): 775-778.
[12]	郝世杰, 邹建鹏, 卫晨, 刘清江. 综合呼吸训练对老年帕金森病病人运动减少型构音障碍的影响[J]. 实用老年医学, 2024, 38(8): 783-787.
[13]	向超, 罗彩东. 心电图avL导联T波变化对老年冠心病病人冠脉狭窄程度的诊断价值[J]. 实用老年医学, 2024, 38(8): 788-791.
[14]	李慧颖, 蔡力力, 朱启伟. 血浆N末端脑钠肽前体对高龄左室肥厚病人预后的预测价值[J]. 实用老年医学, 2024, 38(8): 797-801.
[15]	王新平, 谢柏梅, 卫国, 叶晓莉, 赵亚芸, 谭小田. 老年特发性间质性肺炎病人血清S100A9及sCD163表达水平及临床意义[J]. 实用老年医学, 2024, 38(8): 802-807.